

---

## Heliospectra - Transitory quarter with secured growth capital

Redeye provides an update following Heliospectra's Q1'23 report, where an increased gross margin, a well-controlled cost basis, and management's anticipation of robust order intake in Q2'23 support an optimistic outlook. Sales and order intake came in slightly lower than expected. Hence, we have made a few minor changes to our near-term estimates. Our fair value range, however, remains unchanged, with a base case of SEK1.9 per share.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Heliospectra - Transitory quarter with secured growth capital](#)